Anzeige
Mehr »
Mittwoch, 10.09.2025 - Börsentäglich über 12.000 News
Warum diese Aktie jetzt das perfekte Chance-Risiko-Profil für Investoren bietet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7QK | ISIN: GB0034330679 | Ticker-Symbol: DWV
Berlin
09.09.25 | 19:27
0,055 Euro
-16,67 % -0,011
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ANGLE PLC Chart 1 Jahr
5-Tage-Chart
ANGLE PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0460,05009.09.

Aktuelle News zur ANGLE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiDelveInsight Business Research, LLP: Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight210The open-angle glaucoma market is projected to grow steadily, driven by the rising global prevalence of glaucoma due to aging populations and increasing awareness of early diagnosis. Additionally...
► Artikel lesen
DiShares in Angle tumble on gloomy outlook2
DiAngle H1 Pre-tax Loss Widens, Lowers FY25 Guidance; Stock Down4
ANGLE Aktie jetzt für 0€ handeln
DiAngle shares suffer as interim loss widens amid weaker revenue3
DiAngle PLC Announces Change of Adviser91APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating...
► Artikel lesen
DiAngle PLC Announces Interim Results104ANGLE plc("ANGLE" or "the Company")Interim Results for the six months ended 30 June 2025COMMERCIALISATION PROGRESSED ACROSS MULTIPLE FRONTS DESPITE REVENUE PRESSURE FROM ADVERSE MARKET CONDITIONSLarge...
► Artikel lesen
FrAngle PLC Announces Notice of Results189ANGLE plc ("the Company") Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESS Newswire / September 5, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with...
► Artikel lesen
FrANGLE plc legt Halbjahresergebnisse am 9. September vor2
FrLONDON - ANGLE plc to release interim results on September 92
20.08.Angle teams up with Myriad Genetics on cancer patient blood testing1
20.08.ANGLE plc partners with Myriad Genetics to advance cancer diagnostics2
20.08.ANGLE plc: ANGLE Announces Collaboration with Myriad Genetics169Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test GUILDFORD, SURREY / ACCESS Newswire / August 20,...
► Artikel lesen
08.07.Studie mit Parsortix-System von ANGLE deckt genetische Vielfalt in Tumor-Clustern als Metastasen-Treiber auf1
08.07.Angle PLC Announces Parsortix Enables Study Of Cancer Progression 675New publication in Nature Genetics using Parsortix identifies CTC clusters as promising targets to stop the spread of cancer GUILDFORD, SURREY / ACCESS Newswire / July 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY)...
► Artikel lesen
30.06.ANGLE PLC Announces Result of 2025 Annual General Meeting538Result of 2025 Annual General Meeting GUILDFORD, SURREY / ACCESS Newswire / June 30, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General...
► Artikel lesen
30.06.ANGLE plc shareholders approve all resolutions at annual meeting4
30.06.ANGLE plc Aktionäre genehmigen alle Beschlüsse auf Jahresversammlung3
17.06.Angle develops new prostate cancer liquid biopsy assay2
17.06.Angle PLC - EACR 2025: Innovation in AR Expression Profiling223ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profilingPoster presentation highlights development of a novel CTC-based assay GUILDFORD, SURREY / ACCESS...
► Artikel lesen
17.06.Angle PLC - EACR 2025: Data Demonstrating DNA Dual Analysis218ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILINGPoster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour heterogeneity...
► Artikel lesen
Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1